Industry sources revealed on October 19th that South Korean companies, Ililas Biologics and 카지노 바카라, are currently conducting clinical trials for their promising candidates in Australia and the United States.
Ililas Biologics recently reported the successful completion of dosing and evaluation for the Phase 1 clinical trial of 'ILB-202 (development code name),' a therapy designed for acute kidney injury following heart surgery. This therapy is the lead candidate in their pipeline.
The company stated, "The Phase 1 trial employed random allocation, placebo control, and double-blind testing to assess the safety and pharmacokinetics of ILB-202 in healthy adults." Furthermore, "Across three different cohorts - low dose, medium dose, and high dose - ILB-202 was administered as a single intravenous injection to a total of 18 healthy adult volunteers."
According to the company, no "Serious Adverse Events (SAE)" occurred in any of the three cohorts. Notably, Ililas Biologics received approval for the Phase 1 clinical trial of ILB-202 from the Human Research Ethics Committee (HREC) in Australia in April of the previous year, marking a significant milestone as the first South Korean company to embark on global clinical development of an exosome-based therapy.
A company representative remarked, "We are presently making internal preparations for the Phase 2 clinical trial, with the pace adjusted to align with market conditions." Additionally, the representative highlighted, "Our company is actively collaborating on research with both domestic and international pharmaceutical firms, with an eye on achieving tangible technology transfer outcomes in the future."
In April, 카지노 바카라 initiated its first patient trial for 'BRE-AD01,' a treatment for severe atopic dermatitis in the United States. The clinical trial aims to evaluate the safety, pharmacokinetics, and initial efficacy of BRE-AD01 in different dosages among 27 patients aged 18 and above with moderate to severe atopic dermatitis in the United States.
BRE-AD01, developed using 카지노 바카라's unique exosome platform technology (BG-Platform), harnesses exosomes produced through stem cell immunosuppression activation technology, tailored for stem cell lines (BxC).
카지노 바카라 successfully secured a Series C investment of .9 million last month. The company intends to utilize these funds to expedite the Phase 1 completion of BRE-AD01 and initiate non-clinical studies for the myocardial infarction treatment 'BRE-MI01.' A company representative stated in an interview with HitNews, "Our goal is to wrap up Phase 1 of BRE-AD01 by the third quarter of the coming year, with a focus on global technology transfer, and we are actively conducting clinical trials in the United States."
An industry insider stressed, "South Korean exosome-based therapy development companies are entering international clinical trials with the aim of achieving global technology transfer." The insider further emphasized the importance of preparatory work for planned clinical trials in the United States, including pre-IND meetings with the Food and Drug Administration (FDA).